Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05767723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Platelet Sub-study of the Neomindset Trial

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 8, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 6, 2024 to May 30, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Mar 6, 2024 to Jun 30, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention. The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or dual antiplatelet therapy.
Trial Details
NCT Number NCT05767723
Lead Sponsor Hospital Israelita Albert Einstein
Conditions
(from sponsor)		 Acute Coronary Syndrome
Related terms Acute Coronary Syndrome
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov